Common abnormal results of pap and human papillomavirus cotesting: what physicians are recommending for management
- PMID: 21099599
- DOI: 10.1097/AOG.0b013e3181fae4ca
Common abnormal results of pap and human papillomavirus cotesting: what physicians are recommending for management
Abstract
Objective: To evaluate the association between physician and practice characteristics and adherence to management guidelines to better understand the factors associated with different screening recommendations by primary care physicians.
Methods: We used a cross-sectional nationally representative survey of 950 primary care physicians familiar with human papillomavirus (HPV) testing to assess adherence to management guidelines by analyzing responses to two clinical vignettes of a 35-year-old woman who had Pap and HPV tests results: 1) discordant (normal Pap and positive HPV) or 2) mildly abnormal (atypical squamous cells of undetermined significance Pap and negative HPV). Analyses included multivariable logistic regression.
Results: For the discordant test results, 54.3% (95% confidence interval [CI] 51-57.6%) of physicians recommended both Pap and HPV testing in 6-12 months, adhering to management guidelines. For the mildly abnormal results, only 12.2% (95% CI 10-14.7%) had a guideline-adherent recommendation of Pap testing in 12 months with no HPV test. In multivariable analyses, no significant difference among physicians' specialties was observed for the discordant results. For the mildly abnormal results, physician specialty was associated with guideline adherence in which obstetrician-gynecologists had the highest percent of adherence (19.8%) compared with family and general practitioners (9.3%) and internists (11%) (P<.001).
Conclusion: Even for the most common abnormal results, many physicians reported recommendations that did not adhere to current management guidelines. Evidence-based interventions are needed to improve adherence to management guidelines for the newer HPV DNA test.
Similar articles
-
Primary Care Physicians' Adherence to Expert Recommendations for Cervical Cancer Screening and Prevention in the Context of Human Papillomavirus Vaccination.Sex Transm Dis. 2016 Jul;43(7):438-44. doi: 10.1097/OLQ.0000000000000458. Sex Transm Dis. 2016. PMID: 27322046 Free PMC article.
-
Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending?Arch Intern Med. 2010 Jun 14;170(11):977-85. doi: 10.1001/archinternmed.2010.134. Arch Intern Med. 2010. PMID: 20548011
-
Human papillomavirus (HPV) testing in the management of women with abnormal Pap smears. Experience of a colposcopy referral clinic.Eur J Gynaecol Oncol. 2004;25(5):577-84. Eur J Gynaecol Oncol. 2004. PMID: 15493169
-
Are Health Care Professionals Prepared to Implement Human Papillomavirus Testing? A Review of Psychosocial Determinants of Human Papillomavirus Test Acceptability in Primary Cervical Cancer Screening.J Womens Health (Larchmt). 2020 Mar;29(3):390-405. doi: 10.1089/jwh.2019.7678. Epub 2019 Sep 3. J Womens Health (Larchmt). 2020. PMID: 31479381 Review.
-
Human papillomavirus testing in primary cervical screening and abnormal Papanicolaou management.Obstet Gynecol Surv. 2006 Jun;61(6 Suppl 1):S15-25. doi: 10.1097/01.ogx.0000221011.01750.25. Obstet Gynecol Surv. 2006. PMID: 16729900 Review.
Cited by
-
Impact of an educational tool on young women's knowledge of cervical cancer screening recommendations.Cancer Causes Control. 2022 Jun;33(6):813-821. doi: 10.1007/s10552-022-01569-8. Epub 2022 Mar 21. Cancer Causes Control. 2022. PMID: 35312891 Free PMC article. Clinical Trial.
-
Assessing Physician Adherence to Guidelines for Cervical Cancer Screening and Management of Abnormal Screening Results.J Low Genit Tract Dis. 2020 Oct;24(4):337-342. doi: 10.1097/LGT.0000000000000558. J Low Genit Tract Dis. 2020. PMID: 32976292 Free PMC article.
-
Uptake of HPV testing and extended cervical cancer screening intervals following cytology alone and Pap/HPV cotesting in women aged 30-65 years.Cancer Causes Control. 2018 Jan;29(1):43-50. doi: 10.1007/s10552-017-0976-x. Epub 2017 Nov 9. Cancer Causes Control. 2018. PMID: 29124542 Free PMC article.
-
Patient concerns about human papillomavirus testing and 5-year intervals in routine cervical cancer screening.Obstet Gynecol. 2015 Feb;125(2):317-329. doi: 10.1097/AOG.0000000000000638. Obstet Gynecol. 2015. PMID: 25568994 Free PMC article.
-
Opting out of cervical cancer screening: physicians who do not perform pap tests.Am J Prev Med. 2014 Sep;47(3):315-9. doi: 10.1016/j.amepre.2014.04.018. Epub 2014 Jun 18. Am J Prev Med. 2014. PMID: 24953518 Free PMC article.
References
-
- Saraiya M, McCaig LF, Ekwueme DU. Ambulatory care visits for Pap tests, abnormal Pap test results, and cervical cancer procedures in the United States. Am J Manag Care 2010;16:e137–44.
-
- Siebers AG, Klinkhamer PJ, Grefte JM, Massuger LF, Vedder JE, Beijers-Broos A, et al. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial. JAMA 2009;302:1757–64.
-
- Saslow D, Runowicz CD, Solomon D, Moscicki AB, Smith RA, Eyre HJ, et al; American Cancer Society. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002;52:342–62.
-
- Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D; 2006 ASCCP-Sponsored Consensus Conference. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis 2007;11:201–22.
-
- Wright TC Jr, Schiffman M, Solomon D, Cox JT, Garcia F, Goldie S, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 2004;103:304–9.
